Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Epizyme Inc (NASDAQ:EPZM) shares were halted ahead of an Adcom meeting scheduled for Wednesday.
FDA's Oncologic Drugs Advisory Committee will discuss Epizyme's NDA for tazemetostat tablets, an EZH2 inhibitor, for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
A Rare Disease With Less Effective Treatment
Epithelioid sarcoma is a rare and serious soft tissue sarcoma, or STS, with a high rate of local recurrence and distant metastasis. Diagnosis of epithelioid sarcoma presents a challenge, as it presents symptoms similarly to other benign or malignant neoplasms, and therefore are not diagnosed until it has progressed to late stage.
Most treatment options for epithelioid sarcoma are chemo agents, which produce low response rates and substantial toxicities.
Related Link: 8 Biotech Stocks Morgan Stanley Recommends For 2020
Staffers Question Benefit-Risk Profile
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The briefing document prepared by FDA staffers ahead of the meeting and made public Monday showed staffers acknowledge the need for new therapies with a favorable risk-profile.
FDA staffers, however, are "concerned that there may be insufficient evidence at this time to conclude that tazemetostat confers benefit in patients with epithelioid sarcoma."
The objective response rate, or ORR, for tazemetostat in epithelioid sarcoma, according to the pooled data from Cohorts 5 and 6, was 13%, with a 95% confidence interval, the FDA said. Therefore, the agency believes true estimated response rate could be as low as 4% to 7%, which is inferior to 24% ORR for doxorubicin, which was approved for STS in 1974.
Street Less Optimistic
Tazemetostat is Epizyme's lead drug being evaluated in multiple indications. The candidate is studied in a mid-stage trial as a monotherapy for relapsed/refractory follicular lymphoma among other indications.
Epithelioid sarcoma is a relatively small indication, with a market opportunity at less than $50 million compared to the $500 million opportunity presented in follicular lymphoma, Fierce Biotech quoted Jefferies analyst Michael Yee as saying.
On Wednesday afternoon, the FDA advisory committee voted unanimously in favor of tazemetostat for the treatment of patients with epithelioid sarcoma.
The stock closed up 10.5% at $20.10 per share.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.